Background-Triglycerides and their lipoprotein transport molecules are risk factors for heart disease. Observational studies have associated elevated levels of serum urate (SU) with triglycerides and risk of heart disease. However, owing to unmeasured confounding, observational studies do not provide insight into the causal relationship between SU and triglyceride. The aim of this study was to test for a causal role of SU in increasing triglyceride using Mendelian randomization that accounts for unmeasured confounding. Methods and Results-Subjects were of European ancestry from the atherosclerosis risk in communities (n=5237) and Framingham heart (n=2971) studies. Mendelian randomization by the 2-stage least squares regression method was done with SU as the exposure, a uric acid transporter genetic risk score as instrumental variable, and triglyceride as the outcome. In ordinary linear regression, SU was significantly associated with triglyceride levels (β=2.69 mmol/L change in triglyceride per mmol/L increase in SU). However, Mendelian randomization-based estimation showed no evidence for a direct causal association of SU with triglyceride concentration-there was a nonsignificant 1.01 mmol/L decrease in triglyceride per mmol/L increase in SU attributable to the genetic risk score (P=0.21). The reverse analysis using a triglyceride genetic risk score provided evidence of a causal role for triglyceride in raising urate in men (P Corrected =0.018). Conclusions-These data provide no evidence for a causal role for SU in raising triglyceride levels, consistent with a previous Mendelian randomization report of no association between SU and ischemic heart disease. (Circ Cardiovasc Genet. 2014;7:830-837.)
levated serum urate (SU) levels are a key risk factor for gout and nephrolithiasis. Hyperuricemia and gout are independently associated with all cause and cardiovascular disease (CVD) mortality and myocardial infarction in multivariate analyses. [1] [2] [3] Clinical trials demonstrate cardiovascular benefits by lowering of elevated SU levels (reviewed in 4). However, an older meta-analysis did not fully support association of SU with coronary heart disease, with associative evidence decreased in studies that included adjustment for a wider range of possible confounders. 5 More recently, application of Mendelian randomization has provided no evidence for a causal role of urate in ischemic heart disease. 6 Therefore, the potential causal role of hyperuricemia in the various categories of heart disease remains unresolved. 7 
Clinical Perspective on p 837
One risk factor for CVD is triglyceride that, although not directly atherogenic, is an important biomarker of CVD risk owing to inclusion in atherogenic lipoproteins. 8 Urate levels are positively associated with triglyceride levels independently of metabolic syndrome components, 9 consistent with the possibility that urate could influence CVD risk through triglyceride levels. One approach to evaluate a possible causeeffect role for urate in a complex condition, such as CVD, is to evaluate relationships with subphenotypic, and presumably less complex, risk factors, such as triglyceride levels. A genome-wide association study has identified 28 loci that explain a small proportion (≈6%) of SU levels in European Caucasians. 10 Half of this explained variance (≈3%) is attributed to renal and gut molecules (SLC2A9, SLC17A1, SLC22A11, SLC22A12, ABCG2) that regulate SU levels via regulation of excretion. 10, 11 Mendelian randomization, that exploits random assignment of alleles at conception, is a statistical genetics approach that can allow disentangling of cause and effect in the presence of potential confounding. 12, 13 Given the relatively strong effect on urate levels, a genetic risk score comprised of the SU-associated variants at each locus or individual genetic variants is useful as an instrumental variable to test for a possible causal role for urate in related phenotypes. The Mendelian randomization technique has been used to provide evidence against a causal role for urate in ischemic heart disease, metabolic syndrome, and reduced renal function. 6, 14, 15 Conversely, use of a weight genetic instrumental variable demonstrates a causal role for increased body mass index (BMI) in raising urate levels (demonstrating BMI as an important confounding factor in observational studies of urate and metabolic conditions). 6, 16 Our aim, therefore, was to use Mendelian randomization to test for a causal role for urate (the exposure) in raising triglyceride levels (the outcome), with the results expected to provide additional information to address the broader question of whether urate is causal in CVD.
Subjects and Methods

Subjects
Subjects of European ancestry were included from the atherosclerosis risk in communities (ARIC; n=5237) and the Framingham heart study (FHS; n=2971). Demographic and clinical details of these study sets are described in Table I in the Data Supplement. People taking antihypertensive medication and who self-reported physiciandiagnosed kidney disease or gout were excluded from the analysis. The research procedures were in accordance with the ethical standards of the institutional review boards relevant to the ARIC and FHS data sets. Written informed consent was given by all participants.
Instrumental Variable and Statistical Analysis
The Mendelian randomization approach, 2-stage least squares regression, was performed using a genetic risk score as an instrumental variable. The uric acid transporter instrumental variable comprised single nucleotide polymorphisms (SNPs) rs11942223 (SLC2A9), rs2231142 (ABCG2), rs1183201 (SLC17A1), rs2078267 (SLC22A11), and rs3825018 (SLC22A12) for both ARIC and FHS. A triglyceride instrumental variable was also used, 17 composed of rs10889353 (ANGPTL3), rs7557067 (APOB), rs2954029 (TRIB1), rs7819412 (XKR6-AMAC1L2), rs328 (LPL), rs3135506 (APOA5), rs662799 (APOA5), rs17216525 (NCAN-CLIP2-PBX4), and rs7679 (PLTP). An allele-counting genetic risk score consisted of each SNP coded 0 to 2 based on the number of alleles that associated with increased SU or triglyceride, and scores were combined. Because the uric acid transporter genetic risk score was an adequate instrumental variable (Table 1) , we did not use other SNPs with weaker effects on urate. 10 We excluded from the triglyceride instrumental variable SNPs from the glycolytic locus GCKR and the MLXIPL locus (which includes the BAZ1B gene) because they are both also associated with SU, 10 and there is evidence for pleoitropic effects of these loci on other SU-and triglyceride-related phenotypes. 18, 19 The individual genetic variants of the SU genetic risk score were also used as instrumental variables, as previously described. 14 To test for a causal effect of SU on triglyceride levels, the change in SU resulting from the SU genetic risk score instrumental variable in the ordinary least squares regression (step 1) was regressed against triglyceride levels (outcome; step 2). The estimates derived from the ordinary least squares regression between the explained variables (SU and triglyceride) and the 2-stage least squares regression were then compared using the Durbin-Hausman test. 20 The reverse Mendelian randomization analysis with triglyceride as exposure and SU as outcome was done using the triglyceride genetic risk score described above.
All analyses were done using STATA version 8.0 (StataCorp, College Station, TX). The 2-stage least squares analyses were conducted using the ivreg function on STATA 8.0, where the exposure represented the endogenous variable, outcome the dependent variable, and the appropriate genetic risk score the instrumental variable. Normal linear regression analyses were performed using the regress function on STATA 8.0. A P<0.05 was regarded as significant. A correction factor of 9 was applied for multiple testing (combined and separate data sets including sex analysis). All associations were adjusted for possible confounders (age, sex, and BMI), the first 2 eigen values of genome-wide SNP and principal component analysis (PCA), and by data set when ARIC and FHS were combined, as previously described. 14 
Power Calculations
Power using the SU instrumental variable was calculated as described 21 (http://glimmer.rstudio.com/kn3in/mRnd/), using α=0.05 and parameters from Tables 1 and 2 and Table I in the Data Supplement. Power calculations were done in the combined ARIC/ FHS sample sets and in males and females separately. β OLS was the crude and β XY (an estimate of the unknown true causal relationship) the confounder adjusted regression estimate of urate on triglyceride. Power in the combined samples was 0.94, was 0.46 in males only, and was 0.86 in females only (with a stronger instrumental variable and less variance in triglyceride levels).
Results
Mean SU and serum triglyceride levels according to uric acid transporter genetic risk score are shown in Table II in the Data Supplement. There was, as expected, a clear relationship between increased genetic risk score and SU, with the genetic risk score explaining 2.15%, 2.26%, and 2.23% of variance in SU in the ARIC, FHS, and combined cohorts, respectively (Table 1) . However, as the genetic risk score increases, no clear change was observed in serum triglycerides in any of the study groups (Table II in the Data Supplement).
Mendelian randomization was performed using the 2-stage least squares approach. The ordinary least squares regression analysis showed that an increase of 1 mmol/L in SU was associated with a significant increase in triglyceride levels (β=2.69 mmol/L, P=1.80×10
; Figure 1 and Table 2 ). However, use of the 2-stage least squares approach as a quantitative measure for the exposure (SU) on outcome (serum triglyceride) showed no evidence for a causal role of SU in raising serum triglyceride levels in any sample set, as no significant change was observed in triglyceride values from each unit increase in SU attributable to the genetic risk score using 2-stage least squares (P>0.05; Figure 1 and Table 2 ). Notably, each genetically attributed unit increase in SU was consistently associated with a decrease in The use of an instrumental variable in Mendelian randomization requires that it fulfill 3 assumptions. 13 The instrument used should be (i) adequately correlated with the exposure (SU), (ii) independent from confounders (eg, age, sex, and BMI), and (iii) would influence the outcome via the exposure and not via any pleiotropic effects. The urate instrument satisfies assumption (i) in Europeans (Table 1) , where the F-statistic is ≈≥30 in all analyses. Regarding assumption (ii), we tested by linear regression for association between the uric acid transporter instrumental variable and major confounders age, sex, and BMI, in addition to estimated glomerular filtration rate, systolic blood pressure, highand low-density cholesterol, and ancestry using eigen values from PCA-there was no evidence for association with any of these variables excep PCA1 (Table IV in the Data  Supplement) . This association was observed in the FHS data The left side is the standard linear (ordinary least square) regression between the explained variables (SU and serum triglyceride) and the right side is the 2-stage least squares analysis.
ARIC indicates atherosclerosis risk in communities; BMI, body mass index; FHS, Framingham heart study; and SU, serum urate. *Beta represents the change in serum triglyceride (mmol/L) attributed to a unit change in SU in the linear regression (on the left) and the change in serum triglyceride (mmol/L) caused by a unit change in SU attributed to the instrumental variable in the 2-stage least squares analysis (on the right).
†Standard error. ‡Durbin-Hausman P value. §Unadjusted. ║Adjusted by study data set (in combined), sex (in All), age, BMI, and the first 2 eigen values of genome-wide principal component analysis (in ARIC, FHS, and combined). set, presumably caused by the familial correlation within the FHS. However, there was no evidence for association of triglyceride with PCA1 in the FHS sample set (age, sex, BMI adjusted; P=0.30), arguing against violation of assumption 2 caused by the familial structure. For assumption (iii), the possibility of pleiotropic effects (ie, effects on triglyceride levels aside from or in addition to a direct effect of the urate exposure) of the uric acid transporter instrumental variable on triglyceride levels is difficult to eliminate.
14 To mitigate possible violations of assumption (iii), the 2-stage least squares Mendelian randomization was adjusted by age, sex, BMI, and eigen vectors. Previously, using the same genetic risk score as an instrumental variable in 2-stage least squares Mendelian randomization, we provided evidence for a protective role of urate on renal function.
14 However, the effect size of the individual component SNPs of the genetic risk score on urate did not correlate with the 2-stage least squares effect estimate on renal function.
14 Therefore, here, the individual variants were also tested (Table 3) . At rs11942223 (SLC2A9) and rs2078267 (SLC22A11), negative β values and significant Durbin-Hausman P values were observed, suggesting that these variants may causally influence triglyceride levels, with lifetime exposure to the urate-increasing allele correlating with reduced serum triglyceride (Table 3 ; β=−0.408 mmol/L, P Durbin-Hausman <0.00001 and β=−5.262 mmol/L, P Durbin-Hausman =0.002, respectively).
Finally, we performed the reverse Mendelian randomization testing for a causal role for triglyceride in altering SU levels (Table 4 and Figure 2 ; Table III 
Discussion
Use of the uric acid transporter genetic risk score in the 2-stage least squares Mendelian randomization procedure showed that each standard unit increase in SU because of the genetic risk score was not directly associated with increased serum triglyceride levels. However, the significant Durbin-Hausman P values did provide some evidence for reverse causality, with an increased uric acid transporter genetic risk score associated with reduced triglyceride levels, in a direction opposite to the relationship between SU and serum triglyceride. The analysis of the individual genetic variants, rs11942223 (SLC2A9) and rs2078267 (SLC22A11), in particular, also provided evidence by the Durbin-Hausman test for a causal effect of the urate-increasing alleles of the variants in lowering triglyceride levels. It is not feasible to eliminate the possibility of residual confounding contributing to this observation. Given a possibly weak causal relationship which would reduce power, it will be important to provide more evidence for the potential reverse causation by testing for association of increased uric acid transporter genetic risk score with reduced triglyceride levels by 2-stage least squares analysis in larger cohorts than those studied here. However, we were adequately powered to detect a causal relationship equivalent to the confounder-adjusted population ordinary least squares regression of urate on triglyceride (Table 2) .
Whether the effect of rs11942223 and rs2078267 owes to urate per se or to other pleiotropic effects that can be ascribed to the physiological (functional) effect tagged by these SNPs (which would violate the third requirement of a Mendelian randomization instrumental variable) is unclear. Similar 2-stage least squares analysis that provided evidence for a protective role in renal function of the same urate-increasing genetic variants used here concluded that this effect was consistent with the possibility that the physiological action of the genetic variants (rs2078267 in SLC22A11 encoding OAT4, in particular) in raising SU is responsible for the improved renal function. 14 The strongest evidence here by the Durbin-Hausman test of a causal role for increased urate to reduce triglyceride levels came from rs11942223 (SLC2A9; P<0.0001), with support also from rs2078267 in SLC22A11 (Table 3 ). Arguing against a role for SU per se causing the triglyceride-lowering effect are the data from ABCG2 rs2231142-this instrumental variable was strong (F=61.14, r 2 =0.0074)-yet, the β in the 2-stage least squares analysis was +1.211 mmol/L (indicating the SU-raising genetic effect of rs2231142 could also raise triglyceride levels) with a nonsignificant Durbin-Hausman P of 0.29. The possibility of the activity of ABCG2 concomitantly raising SU and serum triglyceride requires testing in a larger sample set. With respect to the SLC2A9 effect, one environmental exposure relevant to both urate and triglyceride levels is sugar-sweetened beverage consumption. The SLC2A9 transporter exchanges sugars (glucose and fructose) for uric acid, with uric acid transport modified by fructose and glucose. 22, 23 Controlled feeding studies show that consumption of sugar-sweetened beverage increases both SU and serum triglyceride, 24, 25 and consumption of sugar-sweetened beverage is associated with increased SU and serum triglyceride. [26] [27] [28] Collectively, these observations make it conceivable that the activity of SLC2A9 in raising urate lowers triglyceride levels, for example, by influencing the availability of sugar for triglyceride synthesis via glycolysis. Together with our previous Mendelian randomization study testing for a causal role for urate in renal function, 14 these results emphasize the difficulty of identifying a urate instrumental variable for studying the causal relationship of urate with various metabolic phenotypes that has no pleiotropic effects. Although this could be regarded as a deficiency, studies such as this do, however, allow new biological insights into physiological aspects of urate metabolism and generation of testable experimental hypotheses. For example, what are the urate and triglyceride-related phenotypes of rodent models humanized for the individual instrumental variables that indicate pleiotropic effects?
The reverse Mendelian randomization analysis by 2-stage least squares provided direct evidence for a role of triglyceride in increasing urate levels in males only (Figure 2 and Table 4) , with consistent and significant effect sizes attributable to the triglyceride genetic risk score observed in each of the ARIC and FHS cohorts. The effect is in a direction consistent with the observational data, as evidenced by positive 2-stage least squares β values and nonsignificant Durbin-Hausman P values. A similar triglyceride instrumental variable to that used by us (ours excluded MLXIPL) was previously used as an instrumental variable in a Mendelian randomization study that reported evidence of a protective role for raised serum triglyceride in type 2 diabetes but no evidence for a causal role in glucose levels or insulin resistance. 17 These findings are ostensibly incongruous. Furthermore, given the established observational positive relationship between urate and these traits, our evidence supporting a causal role for triglyceride in raising urate is not obviously consistent, with no causal role for triglyceride in glucose levels or insulin resistance. The findings using this triglyceride genetic instrumental variable, and the individual components, need to be extended in a larger Mendelian randomization study that provides adequate power for evaluating the individual components to disentangle the complex cause-effect relationship between triglyceride and other metabolic phenotypes.
One possible deficiency in our study design requires noting. The inherent property of Mendelian randomization should ensure that confounding owing to sugar-sweetened beverage exposure, for example, is ruled out by equivalent lifetime exposure between the randomized genotype groups. However, this is based on the assumption of no effect modification by such confounders on the instrumental variable. In the case of The left side is the standard linear (ordinary least square) regression between the explained variables (SU and serum triglyceride) and the right side is the 2-stage least squares analysis.
ARIC indicates atherosclerosis risk in communities; BMI, body mass index; FHS, Framingham heart study; and SU, serum urate. *Beta represents the change in SU (mmol/L) attributed to a unit change in triglyceride in the linear regression (on the left) and the change in SU (mmol/L) caused by a unit change in serum triglyceride attributed to the instrumental variable in the 2-stage least squares analysis (on the right).
†Standard error. ‡Durbin-Hausman P value. §Unadjusted. ║Adjusted by study data set (in combined), sex (in All), age, BMI, first 2 eigen values of genome-wide SNP (in ARIC, FHS, and combined).
SLC2A9 rs11942223 and sugar-sweetened beverage exposure, there is evidence for nonadditive interaction on the control of SU-with sugar-sweetened beverage exposure, the main urate-lowering effect of the C-allele is reversed. 26 This possibility was not included in our 2-stage least squares procedure.
Our results provided no evidence for a causal role for urate per se in raising triglyceride levels, a risk factor for CVD. 8 These results are in agreement with those of Palmer et al 6 who, using SLC2A9 rs7442295 (in complete linkage disequilibrium with rs11942223) as an instrumental variable for urate exposure, provided no evidence in a study of 7172 cases and 61 502 controls for a causal association between urate and ischemic heart disease and between urate and blood pressure. The observational studies that show independent association of SU with CVD and risk factors may be confounded by exposure to environmental factors that both raise urate levels and increase risk of CVD, with sugar exposure being a good example. 26, 29 These exposures are difficult to measure and account for in observational studies, and highlight the power of Mendelian randomization, with different genotype groups having equivalent lifetime exposures to such confounders, in studying causal relationships. Our data illuminate a small aspect of the overall urate-CVD relationship, using an instrumental variable that explains a fraction of urate (2.2%) controlled by genetic variation in uric acid transporters. Further research should use Mendelian randomization in larger well-phenotyped cohorts to replicate and extend our findings and to examine the consequence of urate exposure on specific CVD-related phenotypes, such as endothelial dysfunction and inflammation. 
